Explore more publications!

California Health Watch: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on California Health Watch.

Press releases published on October 27, 2025

Twin Waves Wellness Center Integrates Breathwork Into Gentle Touch Chiropractic
Alliance of Leading Experts Launches First-of-Its-Kind Initiative to Redefine Healing and Restore Confidence
ALI Conferences Announces Speaker Lineup for the 13th Annual Strategic Internal Communications – West
TechMatter Launches Cure AR, a Next-Gen AI-Enabled Medical Billing Software to Simplify Healthcare Revenue Management
Qualiphy Launches Patient Specific Prescription (PSP) Infrastructure
Nutraland USA’s Actiz!ng™ Black Ginger Extract Earns GRAS Status
Fortune 50 Healthcare Leader Proves Employee Relocation Experience is the New Advantage in Battle for Top Talent
Solaris Endovascular Reports Positive Six-Month Interim Results for DEScover Trial
Anteris Technologies Announces First Patients Treated in DurAVR® THV Global Pivotal Trial (the “PARADIGM Trial”)
Aurora Spine Launches New Biologics Portfolio
Elixir Medical anuncia resultados clínicos recientes y significativos sobre el Bioadaptador DynamX® que demuestran una reducción de casi el 50 % en las tasas de acontecimiento coronarios en comparación con el tratamiento de referencia actua
Elixir Medical annuncia risultati clinici “late-breaking” significativi per DynamX® Bioadaptor che dimostrano una riduzione vicina al 50% dei tassi di eventi coronarici rispetto all’ attuale standard di cura per l’angioplastica coronarica p
Elixir Medical gibt klinische Late-Breaking-Ergebnisse für DynamX® Bioadaptor bekannt, die eine signifikante Reduzierung von koronaren Ereignisraten um nahezu 50 % gegenüber dem aktuellen PCI-Behandlungsstandard zeigen
Elixir Medical Announces Significant Late Breaking Clinical Results for DynamX® Bioadaptor Demonstrating Nearly 50% Reduction in Coronary Event Rates vs. Current PCI Standard of Care
Elixir Medical annonce de nouveaux résultats cliniques significatifs pour le DynamX® Bioadaptor, démontrant une réduction de près de 50 % des taux d’événements coronariens par rapport à la norme actuelle de soins ICP
Elixir Medical ogłasza przełomowe wyniki badań klinicznych DynamX® Bioadaptor – wskazujące na niemal 50% redukcję częstości występowania nieporządanych incydentów wieńcowych w porównaniu do obecnego standardu leczenia PCI
Amwell® to report third quarter 2025 operating results; company leaders to attend upcoming investor conferences
Neuphoria Therapeutics Adopts Limited-Duration Stockholder Rights Plan to Protect Integrity of Process
Myriad Genetics to Release Third Quarter 2025 Financial Results on November 3, 2025
BioStem Technologies Appoints KPMG as its Independent Registered Public Accountant

Share us

on your social networks:
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms & Conditions